Guthrie R M, Ruoff G E, Rofman B A, Ginsberg D, Karp R R, Brown S M, Shulz G A
Department of Family Medicine and Pharmacology, Ohio State University, Columbus 43210.
Fam Pract. 1988 Mar;5(1):29-35. doi: 10.1093/fampra/5.1.29.
One hundred and eighty-nine adults with acute pharyngitis had culture and serological evaluation for group A beta haemolytic streptococci (GABHS), Mycoplasma pneumoniae, and Branhamella catarrhalis. Sixteen patients had evidence for infection with GABHS, none for M. pneumoniae, and one for B. catarrhalis. For those with GABHS, there was no significant difference between empirical treatment by erythromycin or amoxicillin. For those without GABHS, empirical treatment with erythromycin appeared to result in a statistically significant reduction in cough and a noticeable but less than significant reduction of other symptoms when compared to empirical treatment with amoxicillin. The new formulation of erythromycin utilized in this study (PCE) may be associated with a reduction in gastrointestinal intolerance from that reported with other erythromycin products.
189名患有急性咽炎的成年人接受了A组β溶血性链球菌(GABHS)、肺炎支原体和卡他莫拉菌的培养及血清学评估。16名患者有GABHS感染的证据,无肺炎支原体感染证据,1名有卡他莫拉菌感染证据。对于GABHS感染者,红霉素或阿莫西林经验性治疗之间无显著差异。对于无GABHS感染者,与阿莫西林经验性治疗相比,红霉素经验性治疗似乎在统计学上能显著减轻咳嗽,对其他症状的减轻虽明显但未达显著水平。本研究中使用的红霉素新制剂(PCE)可能与胃肠道不耐受较其他红霉素产品报道的情况有所减轻有关。